Lipocine

LPCN NASDAQ
1.850
+0.030
+1.65%
已收盘, 16:00 07/23 EDT
开盘
1.820
昨收
1.820
最高
1.910
最低
1.811
成交量
20.75万
成交均量(3M)
9.32万
52周最高
2.640
52周最低
1.040
换手率
0.96%
市值
3,991.37万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Lipocine LPCN股票价格,Lipocine股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
展开 >

最近浏览

名称
价格
涨跌幅